Authors
Latest:
Crisis Communication Plans in PharmaThe pharmaceutical industry must have crisis communications prepared now to anticipate unforeseen events—especially those that impact public trust.
Latest:
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentA look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Latest:
Clues on Equity Engagement LevelsA survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Latest:
Restoring Hope in Mental Illness Is a Collective MissionThe importance of equitable approaches to diagnosis and treatment.
Latest:
The Promise and Peril of AI in the Physical WorldThe use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.
Latest:
The 90/10 Issue: Bridging the Gap Between Pharma Focus and Patient NeedsThe pharma industry claims to be patient-centric, but, asks Claus Møldrup, how can this be the case if the evolving user experience isn’t always at the forefront of the industry's mind and informing decisions?
Latest:
From Concept to Commercialization: Pushing the EnvelopeDisruptive strategies are essential to grow the pharma industry.
Latest:
Environmental Sustainability in the Life Sciences Sector: Embedding ChangeFor many years, high energy use and its impact on the environment by businesses within the life sciences sector had been generally overlooked in national and global efforts to combat climate change. But with “carbon neutrality” the new buzzwords, how is the sector embracing this push for change?
Latest:
Powering Pipelines Forward: Approach Science DifferentlyWhy tapping the value generated for the next set of therapies is critical.
Latest:
Exploring Biopharma's Dealmaking Terrain, Roadmap in ChinaA surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.
Latest:
Paving the Path to IPO: How to Build Compliant Financial Systems and ProcessesThursday, April 28, 2022 at 11am PDT | 2pm EDT Are you ready for the challenges of going public? Whether you are a fast-growing biotech company or are currently public and looking for SOX compliance, this webinar will cover how to set up scalable and compliant financial processes.
Latest:
The Future of Obesity Pharmacology: Bridging Evidence Gaps with a New Model for Clinical RegistriesThe challenges in obesity research are significant, but the opportunities for innovation are equally profound.
Latest:
Reimagine Thought Leader Identification: Finding Enrollers and EducatorsKey opinion leaders may not be hard to find, but they are very hard to engage because everybody wants a piece of them.
Latest:
Changing the Paradigm in AI ImplementationHow pharma companies can reduce the risk of failure with AI-based innovations.
Latest:
Can AI Accelerate Clinical Review at FDA?With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Latest:
The Price of Prescriptions: Getting it RightDrug companies face new hurdles in a rapidly changing marketplace. How do they finance new drug development amid the uncertainty?
Latest:
Patient Treatment & Travel: The Need for Stepped-Up SupportDesigning an effective travel and lodging patient hub program in pharma.
Latest:
Transforming Healthcare: Beyond Buzzwords to Purposeful ChangeFor a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.
Latest:
Rethinking Market Strategy within a Patient-Centric EraA panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.
Latest:
Is Community the Next Frontier for Cell and Gene Therapy?Both community and academic delivery models play essential and complementary roles in expanding CGT access.
Latest:
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentA look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Latest:
Industry Predictions For 2023Top industry experts weigh in on what the new year holds for the pharma industry.
Latest:
How Bringing Pharmacovigilance In-House Drives Better Oversight and Faster Data AnalysisFor companies in the life science industry, managing their processes in house on their own platforms proved beneficial.
Latest:
Technology Overload: Addressing Site Challenges of Digital TrialsWebinar Date/Time: Wednesday, August 30, 2023 at 11am EDT
Latest:
3 Reasons US Payers Will Make 2021 a Banner Year for BiosimilarsFollowing a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.
